See our management structure

Dr Ton Rijnders

Dr Ton Rijnders brings a wealth of industry experience, having previously served as the Senior Vice President of Research and Head of Discovery at Organon, later Schering-Plough and Merck. He has brought together the teams that developed two successful immuno-oncology drugs, pembrolizumab and acalabrutinib. Ton has directed Lygature/European Lead Factory and the Oncode Institute, bringing together biotech research, academia and the pharmaceutical industry. Currently, he is a non-executive director of Foresight Research Limited, Trustee for Action Against AMD, a member of the board of directors at Pivot Park Screening Centre, at Cyclotron BV and the Smart BioMaterials Consortium.

Dr Sven Kili, MD

Dr Sven Kili brings deep experience in all stages of cell & gene therapy development, including previous roles as CEO of Immune cell engineering and CAR-T company Antion Biosciences, Head of Development for the CGT division of GSK, and prior to that Head of Development for the cell therapy and regenerative medicine department at Sanofi (Genzyme), which included the clinical development and commercialisation of the first combined ATMP product in the EU and later worldwide. Sven trained as an Orthopaedic surgeon in the UK and South Africa. He currently chairs a number of boards, including UK BIA CGTAC, UK Innovation Hubs, ARM Gene Therapy committee, CCRM Investment Committee and co-chairs ISCT Business Development and Finance committee. He further sits on the CCRM Board, LGC Corporation SAB, ISCT Strategic Advisory Council and Saisei Ventures Investment Board and has a visiting chair at UCL. His current roles include CDO at CCRM and OmniaBio, Partner at Saisei Ventures and Principal at Sven Kili Consulting Ltd.

Prof Francesco Dazzi, MD

Professor Dazzi is a medically trained cell therapy expert. After graduating from Padua University in 1984, he obtained an MD as a haemato-oncologist and a PhD in Experimental Oncology. In 2007 he was appointed as Chair of Stem Cell Biology at the Royal Postgraduate Medical School (part of Imperial College London). Francesco is active at King’s College London as Professor of Regenerative Medicine and Lead of Cellular Therapies. King’s College hosts one of the largest initiatives within this field in all of Europe. He also serves as Medical Lead in BioPharmaceuticals R&D for Cell Therapies at pharma giant AstraZeneca where he is responsible for guiding the strategies for cell therapy clinical applications. His cross-functional team at AstraZeneca takes the biology to accelerate the delivery of new cell therapies to patients.

Dr Ton Rijnders

Dr Sven Kili, MD

Prof Francesco Dazzi, MD

Interested in Korecyte Bio? Contact us or read more about our scientific approach.